

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:



Practitioners associated with the Customer Number:

00490

OR



Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:



The address associated with Customer Number:

00490

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone			Email


Assignee Name and Address:

Endovascular Technologies, Inc.
1360 O'Brien Drive
Menlo Park, CA 94025

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	October 5, 2011
Name	William J. Shaw	Telephone	508-652-8384
Title	Assistant Secretary		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

**LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE
REGARDING CERTAIN PATENT MATTERS
EFFECTIVE THROUGH: December 31, 2011**

I, Timothy A. Pratt, as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Action Medical, Inc.; Adam Acquisition 2001 Inc.; Advanced Bionics Corporation; Advanced Stent Technologies, Inc.; Advanced Stent Technologies, LLC; AFx, Inc.; AMS Medinvent S.A.; Angiomedics Incorporated; Asthmatx Inc.; BEI Medical Systems; BEI Medical Systems Company, Inc.; BEI Medical Systems International, Inc.; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Glens Falls Corp.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Miami Corporation; Boston Scientific Mountain View Corporation; Boston Scientific Neuromodulation Corporation; Boston Scientific Santa Rosa Corp.; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Boston Scientific Technology Inc.; Boston Scientific Wayne Corporation; Broadway Acquisition Corporation; BSC Technology, Inc.; Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; CardioGene Therapeutics, Inc.; Cardiothoracic Systems, Inc.; Cardiovascular Imaging Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Celsion Corporation; Charger Acquisition Corp.; Claude Acquisition Corporation; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CRV Acquisition Corp.; CryoCor, Inc.; CryoVascular Systems, Inc.; Embolic Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidis Medical Technology Corporation; Guidant Corporation; Guidant Foundation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technology Inc.; Heart Technology Manufacturing, Inc.; ID Acquisition Corp.; Incept LLC; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Interventional Therapeutics Corporation; Interventional Therapeutics Int'l; KPS Acquisition Corporation; Labcoat Limited; Laboratoires Corvita S.A.R.L.; Mansfield Scientific, Inc.; Meadox Medicals, Inc.; Meadox Technology, Inc.; Medi-Tech Incorporation; Merger Sub, Inc.; Microvasive, Inc.; MW Medical, Inc.; NAMIC Caribe, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; NAMIC U.S.A. Corporation; Nemo I Acquisition, Inc.; Neuro Interventions, Inc.; New Heart Technology, Inc.; Nilo Holding, S.A.; North American Instrument Corporation; Novoste Puerto Rico Inc.; Odyssey Technologies, Inc.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quantum Medical Corporation; Radio Therapeutics Corporation; Remon Medical Technologies, Ltd.; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider (USA) Inc.; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Schneider-Shiley (USA) Inc.; Scimed Life Systems, Inc.; SciMed Technology, Inc.; Scimed, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Surgimed, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; Trivascular 2, Inc.; TriVascular, Inc.; Van-Tec, Inc.; and Vesica Medical Inc.;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera PoissantReg. No. 56,871
Alana BergmanReg. No. 47,420
James R. ChiapettaReg. No. 39,634
Sara J. CitrowskeReg. No. 55,076
Jeffrey P. CookReg. No. 48,649
Luke R. DohmenReg. No. 36,783
Peter J. GafnerReg. No. 36,517
Lori J. HeinrichsReg. No. 43,667
Albert K. KauReg. No. 40,672

Philip H. LeeReg. No. 50,645
Kurt W. LockwoodReg. No. 40,704
Jeffrey Z. MannReg. No. 51,994
Steven A. McAuleyReg. No. 46,084
Todd P. MessalReg. No. 42,883
Tyler L. NasiedlakReg. No. 40,099
Peter NigrelliReg. No. 66,461
William J. ShawReg. No. 43,111
Kimberly S. ZilligReg. No. 46,346

Timothy A. Pratt, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary

01/13/11

Date

COMMONWEALTH OF MASSACHUSETTS)

COUNTY OF MIDDLESEX) ss.

On this 13th day of January, 2011, before me personally appeared Timothy A. Pratt to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

Notary Public

